Icotrokinra not checked
Johnson & Johnson (Janssen) · JNJ-77242113 · PN-21235
FollowEvery change as it happens, and a Monday email
Trials
10 active
16 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Plaque Psoriasis (5 trials), Arthritis, Psoriatic (2 trials), Generalized Pustular Psoriasis, Erythrodermic Psoriasis, Colitis, Ulcerative, Crohn Disease
- Main trialPhase 3
- “The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).”In the company’s words, NCT06095102 on ClinicalTrials.gov
- Other names
- JNJ-77242113 · PN-21235 · PN-235
Other drugs for Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up3
- 10 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 14 Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- 19 Sep 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 19 Jun 2024 | A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) | |
| Phase 3Active, not recruiting | 29 Jul 2024 | A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Active, not recruiting | 17 Sep 2024 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Active, not recruiting | 15 Nov 2024 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | |
| Phase 3Active, not recruiting | 14 Jan 2025 | A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | |
| Phase 3Active, not recruiting | 17 Nov 2025 | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Active, not recruiting | 25 May 2026 | A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis | |
| Phase 3Active, not recruiting | 10 Feb 2027 | A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | |
| Phase 3Active, not recruiting | 14 Jan 2028 | A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2/3Recruiting | 19 Sep 2028 | A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Completed | 15 Dec 2022 | A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis | |
| Phase 2Completed | 23 Mar 2023 | A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis | |
| Phase 2Completed | 29 Sep 2023 | A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis | |
| Phase 2Completed | 26 Sep 2024 | A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 1Completed | 28 Sep 2022 | A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants | |
| Phase 1Completed | 7 Apr 2023 | A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026